


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|------------------|--|
| <p>(51) International Patent Classification 7 : A61L 29/10</p> | <p>A1</p> | <p>(11) International Publication Number: WO 00/30697 (43) International Publication Date: 2 June 2000 (02.06.00)</p> |
| <p>(21) International Application Number: PCT/US99/27273 (22) International Filing Date: 16 November 1999 (16.11.99) (30) Priority Data: 09/197,815 23 November 1998 (23.11.98) US (71) Applicant: HEALTHSHIELD TECHNOLOGIES LLC [US/US]; Suite 201, 67 Prospect Avenue, West Hartford, CT 06106 (US). (72) Inventors: TROGOLO, Jeffrey, A.; 228 Commonwealth Av- enue, Boston, MA 02116 (US). BARRY, John, E.; 18 Drake Lane, Derry, NH 03038 (US). (74) Agents: GOGORIS, Adda, C. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022-7513 (US).</p> | | <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i></p> |
| <p>(54) Title: ANTIBIOTIC HYDROPHILIC POLYMER COATING</p> <p>(57) Abstract</p> <p>The invention relates to an antibiotic coated substrate having an antibiotic coating composition coated thereon. The coating composition is formed of a hydrophilic polymer having antibiotic ceramic particles, preferably antibiotic zeolite, dispersed therein. The antibiotic zeolite may further comprise a discoloration agent. Another embodiment of the invention is an article comprising a substrate on which is coated the antibiotic hydrophilic coating composition. A method for preparing the antibiotic hydrophilic polymer coating on a substrate is also provided.</p>  | | |

ANTIBIOTIC HYDROPHILIC POLYMER COATING

FIELD OF THE INVENTION

5 This invention relates to hydrophilic polymer coatings having antimicrobial properties.

BACKGROUND OF THE INVENTION

10 A number of metal ions have been shown to possess antibiotic activity, including silver, copper, zinc, mercury, tin, lead, bismutin, cadmium, chromium and thallium ions. It is theorized that these antibiotic metal ions exert their effects by disrupting respiration and electron transport systems upon absorption into bacterial or fungal cells. Antimicrobial metal ions of silver, copper, zinc, and gold, in particular, are considered safe for *in vivo* use. Antimicrobial silver ions are particularly useful for *in vivo* uses due to the fact that they are not substantially absorbed into the body.

15 Silver ions have been impregnated in the surfaces of medical implants, as described in U.S. Patent No. 5,474,797. Silver ions have also been incorporated in catheters, as described in U.S. Patent No. 5,520,664. The products described in these patents, however, do not exhibit an antibiotic effect for a prolonged period of time because a passivation layer typically forms on the silver ion coating. This layer reduces the release rate of the silver ions from the product, resulting in lower antibiotic effectiveness. In addition, the layer containing the silver frequently becomes discolored, causing the products to have a poor appearance. The discoloration is caused by a high flux release rate of silver ion into the surroundings.

20 Antibiotic zeolites can be prepared by replacing all or part of the ion-exchangeable ions in zeolite with antibiotic metal ions, as described in U.S. Patent Nos. 25 4,011,898; 4,938,955; 4,906,464; and 4,775,585. Polymers incorporating antibiotic zeolites have been used to make refrigerators, dish washers, rice cookers, plastic film, chopping boards, vacuum bottles, plastic pails, and garbage containers. Other materials in which antibiotic zeolites have been incorporated include flooring, wall paper, cloth, paint, napkins,

plastic automobile parts, bicycles, pens, toys, sand, and concrete. Examples of such uses are described in U.S. Patent Nos. 5,714,445; 5,697,203; 5,562,872; 5,180,585; 5,714,430; and 5,102,401.

5 Hydrophilic coatings with low friction have been applied to medical devices such as catheters. See, for example, U.S. Patent No. 5,509,899. Such coatings are highly desirable to allow for easy insertion into the body. Hydrophilic coatings, however, are excellent breeding grounds for bacteria.

10 U.S. Patent No. 4,923,450 discloses a catheter having a coating of antibiotic zeolite. U.S. Patent No. 5,100,671 describes a medical article that is formed using silicone rubber that contains antibiotic zeolite. However, use of conventional antibiotic zeolite, such as that described in U.S. Patent No. 4,011,898, results in a catheter which exhibits severe discoloration. For example, a catheter made according to U.S. Patent No. 4,923,450 which has a coating of the antibiotic zeolite material of U.S. Patent No. 4,011,898 adhered to its surface becomes highly discolored within days.

15 A conventional catheter is typically comprised of a hydrophobic polymer. When antibiotic zeolite is incorporated in such a catheter, however, water is unable to reach the zeolite in the bulk of the material. The bulk of the zeolite is, therefore, ineffective against bacteria surrounding the catheter since only the zeolite at the surface of the catheter is active.

20 U.S. Patent No. 5,305,827 describes an antimicrobial hydrophilic coating for heat exchangers. The coating includes silver oxide, to inhibit microbial growth and improve adhesion to the heat transfer surfaces of a heat exchanger. However, this coating exhibits severe discoloration and is typically antimicrobially effective for 3 days or less.

25 Japanese Patent Application No. 03347710 relates to a non-woven fabric bandage containing synthetic fibers and hydrophilic fibers. The synthetic fibers contain zeolite which is ion-exchanged with silver, copper, or zinc ions.

30 U.S. Patent No. 4,923,450 discloses incorporating zeolite in bulk materials. When zeolite is conventionally compounded into polymers, however, the zeolite often aggregates, causing poor dispersion of the zeolite in the polymer. When such material is molded or extruded, the surface of the polymer is frequently beaded instead of flat. Poor dispersion of the zeolite also can cause changes in the bulk properties of the polymer, such as a reduction in tensile strength. Any significant changes in the bulk properties of medical devices, such as catheters, however, result in a need to seek regulatory clearance by the U.S. Food and Drug Administration (FDA), which is a costly and time consuming process.

Furthermore, it has been found by the present inventors that conventionally kneading antibiotic zeolites in many polymeric materials results in a "hazy" appearance and in discoloration. This appears also to result from inadequate dispersion of the zeolite, i.e., the formation of zeolite aggregates in the material, and the inclusion of air or water during the kneading process.

U.S. Patent No. 4,938,958 describes antibiotic zeolites in which a portion of the ion-exchangeable ions in the zeolite are replaced with ammonium. This results in a product which exhibits reduced discoloration. However, as described in U.S. Patent No. 4,938,955, it is often necessary to add an organic discoloration inhibitor, in addition to the antibiotic zeolite, to adequately prevent discoloration of the resin in which the zeolite is incorporated.

Discoloration inhibitors are often not biocompatible and cannot be incorporated into medical devices. Furthermore, incorporation of an organic discoloration inhibitor in the polymeric material of a medical device may cause changes in the bulk properties of the material that are highly undesirable.

Therefore, there is a need for a hydrophilic polymer coating which contains an antimicrobial material which releases antibiotic metal ions and avoids antibiotic particle aggregation. Furthermore, there is a need for a hydrophilic polymer coating which contains an antimicrobial material which does not discolor.

SUMMARY OF THE INVENTION

The invention relates to a substrate having an antibiotic coating composition coated thereon. The coating composition is formed of a hydrophilic polymer having antibiotic ceramic particles dispersed therein, preferably, without substantial aggregation of the particles.

Also, an article is provided comprising a substrate on which is coated an antibiotic hydrophilic coating composition. The coating composition comprises a hydrophilic polymer having antibiotic ceramic particles dispersed therein.

In another embodiment, the invention relates to a coating solution comprising a hydrophilic polymer having antibiotic zeolite particles dispersed therein and an organic solvent.

Yet another embodiment of the invention is a method for preparing an antibiotic hydrophilic coating on a substrate. The method involves applying an antibiotic hydrophilic coating solution comprising a hydrophilic polymer, dispersed antibiotic ceramic particles, and an organic solvent, to the substrate.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a catheter having an antibiotic hydrophilic coating thereon according to the invention.

5 DETAILED DESCRIPTION OF THE INVENTION

All patent applications, patents, patent publications, and literature references cited in this specification are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present description, including definitions, is intended to control.

10 According to the present invention, an antibiotic hydrophilic composition is used to coat a substrate. The composition contains a hydrophilic polymer having antibiotic ceramic particles dispersed therein.

Antibiotic ceramic particles include, but are not limited to, zeolites, hydroxyapatite, zirconium phosphates and other ion-exchange ceramics. Hydroxyapatite particles containing antimicrobial metals are described, e.g., in U.S. Patent No. 5,009,898. 15 Zirconium phosphates containing antimicrobial metals are described, e.g., in U.S. Patent Nos. 5,296,238; 5,441,717; and 5,405,644. Preferably, antibiotic zeolite is employed containing ion-exchanged antibiotic metal ions.

The coating preferably has a thickness of from about 0.1 μm to about 5 mm, more preferably, from about 0.5 μm to about 100 μm and, most preferably, from about 1 to 20 about 50 μm . As will be appreciated by those skilled in the art, however, the optimal thickness of coating employed will depend on the substrate being coated.

Any suitable hydrophilic polymer may be employed, including, for example, polyhydroxyethyl methacrylate, polyacrylamide, polydimethylsiloxane, N-vinyl-2-pyrrolidinone, hydrophilic polyurethane, and the like. Preferably, the hydrophilic polymer is 25 hydrophilic polyurethane, such as the TECOPHILICTM polyurethane sold by Thermedics of Woburn, MA.

An amount of antibiotic ceramic is dispersed in the hydrophilic polymer that is effective to release the antibiotic metal ions in a microbiocidally effective amount. In medical device embodiments of the present invention, the coating preferably exhibits a release rate 30 ranging from about 5 to about 50 ppb of microbiocidally effective silver ions upon contact of the medical device with body tissues or when contaminated outside of the body with, e.g., microbes transferred from uncovered hands, for a period of more than 1 week.

In antibiotic zeolite particles used in the preferred embodiment of the present

invention, ion-exchangeable ions present in zeolite, such as sodium ions, calcium ions, potassium ions and iron ions are partially replaced with ammonium and antibiotic metal ions. Such ions may co-exist in the antibiotic zeolite particle since they do not prevent the bacteriocidal effect. Examples of antibiotic metal ions include, but are not limited to, ions of silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium and thallium. Preferably, the antibiotic metal ions are silver, copper or zinc ions, and most preferably silver is employed. These antibiotic metal ions may be incorporated into the zeolite by themselves or in a mixture.

The antibiotic metal ion is preferably present in the range of from about 0.1 to about 15 wt % of the zeolite based upon 100% total weight of zeolite. In one embodiment, the zeolite contains from about 0.1 to about 15 wt % of silver ions and from about 0.1 to about 8 wt % of copper or zinc ions. Although ammonium ion may be contained in the zeolite at a concentration as high as about 20 wt % or less of the zeolite, it is desirable to limit the content of ammonium ions to about 0.5 to about 2.5 wt % of the zeolite, more preferably from about 0.5 to about 2.0 wt %, and most preferably, from 0.5 to about 1.5 wt %.

Antibiotic zeolites, including the antibiotic zeolites disclosed in U.S. Patent No. 4,938,958, are well-known and may be prepared for use in the present invention using known methods. These include the antibiotic zeolites disclosed in U.S. Patent No. 4,938,958.

Either natural zeolites or synthetic zeolites may be used to prepare the antibiotic zeolites used in the present invention. "Zeolite" is an aluminosilicate having a three dimensional skeletal structure that is represented by the formula: $XM_2/nO \cdot Al_2O_3 \cdot YSiO_2 \cdot ZH_2O$. M represents an ion-exchangeable ion, generally a monovalent or divalent metal ion; n represents the atomic valency of the (metal) ion; X and Y represent coefficients of metal oxide and silica, respectively; and Z represents the number of water of crystallization. Examples of such zeolites include A-type zeolites, X-type zeolites, Y-type zeolites, T-type zeolites, high-silica zeolites, sodalite, mordenite, analcite, clinoptilolite, chabazite and erionite. The present invention is not restricted to use of these specific zeolites.

The ion-exchange capacities of these zeolites are as follows: A-type zeolite = 7 meq/g; X-type zeolite = 6.4 meq/g; Y-type zeolite = 5 meq/g; T-type zeolite = 3.4 meq/g; sodalite = 11.5 meq/g; mordenite = 2.6 meq/g; analcite = 5 meq/g; clinoptilolite = 2.6 meq/g; chabazite = 5 meq/g; and erionite = 3.8 meq/g. These ion-exchange capacities are sufficient for the zeolites to undergo ion-exchange with ammonium and antibiotic metal ions.

The specific surface area of preferred zeolite particles is preferably at least 150 m²/g (anhydrous zeolite as standard) and the SiO₂/Al₂O₃ mole ratio in the zeolite composition is preferably less than 14 and more preferably less than 11.

5 The antibiotic metal ions used in the antibiotic zeolites should be retained on the zeolite particles through an ion-exchange reaction. Antibiotic metal ions which are adsorbed or attached without an ion-exchange reaction exhibit a decreased bacteriocidal effect and their antibiotic effect is not long-lasting. Nevertheless, it can be advantageous for imparting quick antimicrobial action to maintain a sufficient amount of surface adsorbed metal ion.

10 In the ion-exchange process, the antibiotic metal ions tend to be converted into their oxides, hydroxides, and basic salts either in the micropores or on the surfaces of the zeolite and also tend to deposit there, particularly when the concentration of metal ions in the vicinity of the zeolite surface is high. Such deposition tends to adversely affect the bacteriocidal properties of ion-exchanged zeolite.

15 In an embodiment of the antibiotic zeolites, a relatively low degree of ion exchange is employed to obtain superior bacteriocidal properties. It is believed to be required that at least a portion of the zeolite particles retain metal ions having bacteriocidal properties at ion-exchangeable sites of the zeolite in an amount less than the ion-exchange saturation capacity of the zeolite. In one embodiment, the zeolite employed in the present invention retains antimicrobial metal ions in an amount up to 41% of the theoretical ion-exchange
20 capacity of the zeolite. Such ion-exchanged zeolite with a relatively low degree of ion-exchange may be prepared by performing ion-exchange using a metal ion solution having a low concentration as compared with solutions conventionally used for ion exchange.

A preferred antibiotic zeolite for use in the invention is type A zeolite containing either a combination of ion-exchanged silver, zinc, and ammonium or silver and
25 ammonium. One such zeolite is manufactured by Shinagawa, Inc. under the product number AW-10N and consists of 0.6% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about 2.5μm. Another formulation, AJ-10N, consists of about 2% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about 2.5μm. Yet another formulation, AW-80, contains 0.6% by weight of silver ion-exchanged in Type A
30 zeolite particles having a diameter of about 1.0μm. Another formulation, AJ-80N, consists of about 2% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about 1.0μm. These zeolites preferably contain between about 0.5% and 2.5% by weight of ion-exchanged ammonium. The zeolites are often obtained in master batches of low density

polyethylene, polypropylene, or polystyrene, containing 20 wt % of the zeolite.

A discoloration agent may be added to the antibiotic hydrophilic polymer. Preferably, the discoloration agent is biocompatible. Preferred discoloration agents include, but are not limited to, inorganic discoloration inhibitors such as ammonium. More preferably, the inorganic discoloration inhibitor is an ion-exchanged ammonium ion in the antibiotic zeolite. The antibiotic hydrophilic polymer is preferably substantially free of organic discoloration inhibitors.

The antibiotic hydrophilic polymer preferably is also substantially free of aggregates of antibiotic zeolite. Substantial aggregation of the antibiotic zeolite may be prevented by dispersion of the zeolite in the hydrophilic polymer using standard compounding techniques.

The antibiotic hydrophilic polymer preferably contains from about 0.05 to about 10% by weight of antibiotic zeolite based upon 100% total weight of antibiotic hydrophilic polymer. More preferably, the polymer contains from about 0.1% to about 5% by weight of antibiotic zeolite and, most preferably, from about 0.1% to about 1% by weight of antibiotic zeolite.

The substrate employed in accordance with the invention may be any substrate to which the hydrophilic polymer adheres, including, but not limited to, glass, plastic (such as polyurethane, polyethylene, polyvinyl chloride, and polypropylene), metal (such as aluminum, copper, bronze, and stainless steel), and woven and non-woven fabrics.

According to another embodiment of the invention, an article is provided comprising a substrate on which is coated the antibiotic hydrophilic coating. The article may be a medical article, such as a catheter, stent, heart valve, or vascular graft, a component of a heat exchanger, such as the tank, a building product, such as paper, house wrap, or shingles, or a water transport or storage product, such as a pipe or tank liner.

In one embodiment, the coating of the present invention forms an outer and/or inner surface of a medical catheter. Preferably, as shown in Figure 1, the catheter 1 is coated with the antimicrobial hydrophilic coating, on both the outside 3 and inside 5 of the catheter to form a coated catheter 7. The hydrophilic polymer absorbs water, thereby drawing the antibiotic ions in the polymer to the surface of the catheter. Thus, zeolite embedded in the bulk of the polymer is effective against bacteria on the catheter surface. Preferably, the thickness of the coating on the catheter is from about 0.5 to about 100 μm and, more preferably, from about 1 to about 50 μm .

A coating solution is also provided according to the invention which contains the hydrophilic polymer having antibiotic ceramic particles dispersed therein in an organic solvent. Any organic solvent which dissolves the hydrophilic polymer may be employed. Preferred solvents include tetrahydrofuran, dimethylacetamide, methylethylketone, and mixtures thereof.

The coating solution preferably contains from about 0.01 to about 50% by weight solids based upon 100% total weight of the coating solution. More preferably, the coating solution contains from about 0.1 to about 30% by weight solids and, most preferably, from about 1 to about 20% by weight solids.

The solids in the coating solution preferably contain from about 0.01 to about 90% by weight of antibiotic zeolite and from about 10% to about 99.99% by weight of hydrophilic polymer based upon 100% total weight solids. More preferably, the solids comprise from about 0.05 to about 80% by weight of antibiotic zeolite and from about 20% to about 99.95% by weight of hydrophilic polymer. Most preferably, the solids comprise from about 0.1 to about 70% by weight of antibiotic zeolite and from about 30% to about 99.9% by weight of hydrophilic polymer.

The coating solution of the invention may be prepared by first dispersing antibiotic zeolite into the hydrophilic polymer. Any suitable method of dispersion, but preferably high shear mixing with a dual screw compounder, is performed. The hydrophilic polymer containing the dispersed antibiotic particles is then dissolved in the organic solvent.

Another suitable method for preparing the antibiotic coating solution of the invention is as follows. Antibiotic zeolite in an effective amount is dispersed into an organic solvent to form a first solution. The hydrophilic polymer is dissolved in an organic solvent to form a second solution, preferably by mixing the polymer into the solvent at about 20 °C to about 70 °C, more preferably, from about 25 °C to about 60 °C and, most preferably, from about 40 °C to about 60 °C. The heating is performed in an explosion proof container. The concentration of solvent in the second solution preferably ranges from about 0% to about 20% by weight, more preferably, from about 0% to about 15% and, most preferably, from about 0% to about 10%. The first solution and second solution are then mixed to form the antibiotic coating solution of the invention.

The antibiotic hydrophilic coated substrate is prepared by applying the antibiotic hydrophilic coating solution to the substrate. Preferably, the contact time of the coating solution with a polymeric substrate is minimized, since the solvent of the coating solution may

dissolve the polymeric substrate. The coating time, however, should be sufficient to adhere the coating to the substrate. Suitable methods of applying the coating solution to the substrate include, but are not limited to, dipping and spraying. Dipping is preferred. Preferably, when the coating solution is applied, the antibiotic ceramic particles are maintained in suspension in the solution.

A primer may be applied to the substrate before applying the solution polymer to help bond the hydrophilic polymer to the substrate.

If zeolite is not adequately dispersed in the hydrophilic polymer, the zeolite clumps and adheres to polymeric particles. Coatings produced without adequate dispersion in the hydrophilic polymer exhibit low efficacy against bacterial and fungal cells and poor adherence to substrates. Clumping of the antibiotic zeolite powder also results in discoloration of the coating.

The antibiotic properties of the antibiotic zeolite particles of the invention may be assayed using conventional assay techniques, including for example determining the minimum growth inhibitory concentration (MIC) with respect to a variety of bacteria, eumycetes and yeast. In such a test, the bacteria listed below may be employed:

Bacillus cereus var *mycoides*,

Escherichia coli,

Pseudomonas aeruginosa,

Staphylococcus aureus,

Streptococcus faecalis,

Aspergillus niger,

Aureobasidium pullulans,

Chaetomium globosum,

Gliocladium virens,

Penicillium funiculosum,

Candida albicans,

Saccharomyces cerevisiae,

The assay for determining MIC can be carried out by smearing a solution containing bacteria for inoculation onto a plate culture medium.

The present invention will hereunder be explained in more detail with reference to the following non-limiting working examples.

Example 1

A 1" x 1" sample of knitted polyester, available from Bard Vascular Systems Division as knitted polyester style no. 6103, was coated with the antibiotic hydrophilic coating of the present invention as follows.

5 A coating solution containing 2.90% by weight of hydrophilic polyurethane available as Tecophilic™ from Thermedics of Woburn, MA; 96.81% tetrahydrofuran; and 0.29% AW-10N zeolite, available from Shinagawa, Inc., was prepared and mixed with a high shear mixer.

10 An eye dropper was used to apply the coating solution to the polyester sample. The polyester sample was then sprayed with air to remove excess powder and to cure the coating.

Example 2

15 A Dow Shaker Test was performed on the polyester sample prepared in Example 1 (hereafter referred to as Sample A) to determine its inhibitory effect against *S. aureus*. The Dow Shaker Test is based on Dow Corporate Test Method 0923 for testing aerobic bacteria by Dow Chemical. The Dow Shaker Test is described below.

Sample A was sterilized at 121 °C for 15 minutes.

20 A culture tube containing *S. aureus* was prepared by adding one disk of *S. aureus* to the culture tube. From about 2 to 5 ml of broth was added to the culture tube. Then the culture tube was agitated with a vortex mixer until the disk was completely dissolved in the broth. The bacteria in the culture tube was incubated for at least 3 hours at 35 °C. The culture tube was then refrigerated at about 2-8 °C until needed for testing.

25 A 5 ml sample of bacteria from the culture tube was removed and agitated in a vortex mixer. The absorbance of the sample was measured at 475 nm with a spectrophotometer relative to the absorbance of the aforementioned broth. Broth and/or bacteria from the culture tube were added to the sample until an absorbance of about 0.1 absorbance units was obtained. This corresponds to from about 10^5 to about 10^6 colony forming units per milliliter (CFU/ml).

30 5 ml of suspension was extracted from the sample and added to a flask containing 70 ml of sterile buffer. The resulting solution contained from about 10^4 to about 10^5 CFU/ml. The flask was capped and shaken on a wrist action shaker for 1 minute at maximum speed. This is referred to as time "0 hours" below.

The number of colony forming units in 1ml of the solution was determined at

time 0 hours by the following procedure. 1 ml of solution was extracted from the flask and added to a vial containing 9 ml of buffer solution to form a 10:1 dilution. The solution was repeatedly diluted with buffer solution until a plate count of about 30 to about 200 CFU/ml was obtained.

1 ml of the solution from the flask and each dilution were transferred to separate petri dishes. About 15 to 20 ml of molten agar was added to each dish. Each dish was rotated 10 times clockwise and 10 times counter-clockwise to evenly distribute the agar and bacteria. Then each dish was incubated for 18-24 hours at 35 °C. A plate count was performed on the petri dish containing from about 30 to about 200 bacteria colony forming units to determine the number of colony forming units.

Also, at time 0 hours, sample A was added to the flask and shaken with a wrist action shaker for 1 hour. The number of colony forming units in 1 ml of the solution in the flask was determined by the above procedure using 2 petri dishes. If the numbers of colony forming units in the 2 petri dishes were not within 15% of each other, the entire Dow Shaker Test was repeated.

The number of colony forming units in 1ml of the solution was also determined after shaking the flask with a wrist action shaker for 18 and 24 hours.

A control was tested by the same procedure as sample A. The control was an untreated 1" x 1" sample of no. 6103 polyester.

The numbers of colony forming units measured at 0 hours, 1 hour, 18 hours, and 24 hours for sample A and the control are shown in Table 1. The percentages of bacteria killed by sample A and the control at times 1 hour, 18 hours, and 24 hours are shown in Table 2.

Table 1

| Sample | Bacteria Counts of <i>S. aureus</i> (Colony Forming Units) | | | |
|----------|--|-----------|----------|-----------|
| | 0 hours | 1 hour | 18 hours | 24 hours |
| Sample A | 780,000 | 2,145,000 | 85,000 | 3,700 |
| Control | 480,000 | 12,400,00 | 4,720,00 | 4,300,000 |

Table 2

| Sample | % Killed | | |
|----------|----------|----------|----------|
| | 1 hour | 18 hours | 24 hours |
| Sample A | 0 | 89.10% | 99.53% |
| Control | 0 | 0 | 0 |

As indicated in Table 2, Sample A exhibited 99.53 % inhibition of *S. aureus* after 24 hours of contact with the bacteria.

Example 3

Safety and Biocompatibility

Safety and biocompatibility tests were conducted on the antibiotic zeolites employed in the invention. ISO 10993-1 procedures were employed. The following results were obtained:

| |
|---|
| Cytotoxicity: Non-Toxic |
| Acute Systemic Toxicity: Non-Toxic |
| Intracutaneous Toxicity: Passed |
| Skin Irritation Test: Non-Irritant |
| Chronic Toxicity: No Observable Effect |
| <i>In-vitro</i> Hemolysis: Non-Hemolytic |
| 30-day Muscle Implant Test: Passed |
| 60-day Muscle Implant Test: Passed |
| 90-day Muscle Implant Test: Passed |
| Ames Mutagenicity Test: Passed |
| Pyrogenicity: Non-Pyrogenic |

Thus, the antibiotic zeolites are exceptionally suitable under relevant toxicity and biocompatibility standards for use in articles coated with the antibiotic zeolites.

While preferred embodiments of the invention have been described in the foregoing examples, it will be understood by those skilled in the art that various changes and modifications may be made therein without departing from the spirit and the scope of the invention. Accordingly, the above description should be construed as illustrating and not

limiting the scope of the invention.

What is claimed is:

- 1 1. An antibiotic coated substrate comprising an antibiotic coating
2 composition coated on a substrate, said antibiotic coating composition comprising a
3 hydrophilic polymer having antibiotic ceramic particles dispersed therein.
- 1 2. An antibiotic coated substrate according to claim 1, wherein said
2 polymer is selected from the group consisting of polyhydroxyethyl methacrylate,
3 polyacrylamide, polydimethylsiloxane, N-vinyl-2-pyrrolidinone, and hydrophilic
4 polyurethane.
- 1 3. An antibiotic coated substrate according to claim 1, wherein the
2 antibiotic ceramic particles are selected from the group consisting of ion-exchanged zeolite,
3 hydroxyapatite, and zirconium phosphate.
- 1 4. An antibiotic coated substrate according to claim 3, wherein the
2 antibiotic ceramic particles are ion-exchanged zeolite.
- 1 5. An antibiotic coated substrate according to claim 4, wherein said
2 antibiotic metal ion is selected from the group consisting of silver, copper, zinc, mercury, tin,
3 lead, bismutin, cadmium, chromium and thallium.
- 1 6. An antibiotic coated substrate according to claim 1, wherein said
2 polymer further comprises an inorganic discoloration agent.
- 1 7. An antibiotic coated substrate according to claim 4, wherein said ion-
2 exchanged zeolite further comprises ion-exchanged ammonium ions.
- 1 8. An antibiotic coated substrate according to claim 1, wherein said
2 polymer is substantially free of organic discoloration inhibitors.
- 1 9. An antibiotic coated substrate according to claim 1, wherein said
2 polymer is substantially free of aggregates of said antibiotic zeolite.

1 10. An article comprising a substrate on which is coated an antibiotic
2 hydrophilic coating composition, said coating composition comprising a hydrophilic polymer
3 having antibiotic ceramic particles dispersed therein.

1 11. An article according to claim 10, wherein said article is a medical
2 article.

1 12. An article according to claim 11, wherein said article is a catheter.

1 13. An article according to claim 10, wherein said article is a component of
2 a heat exchanger.

1 14. An article according to claim 10, wherein said article is a building
2 product.

1 15. An article according to claim 10, wherein said article is a water transport
2 or water storage product.

1 16. An antibiotic coating solution comprising a hydrophilic polymer having
2 antibiotic ceramic particles dispersed therein and an organic solvent.

1 17. An antibiotic coating solution according to claim 16, wherein said
2 polymer is selected from the group consisting of polyhydroxyethyl methacrylate,
3 polyacrylamide, polydimethylsiloxane, N-vinyl-2-pyrrolidinone, and hydrophilic polyurethane.

1 18. An antibiotic coating solution according to claim 16, wherein the
2 antibiotic ceramic particles are selected from the group consisting of ion-exchanged zeolite,
3 hydroxyapatite, and zirconium phosphate.

1 19. An antibiotic coating solution according to claim 18, wherein the
2 antibiotic ceramic particles are ion-exchanged zeolite.

1 20. An antibiotic coating solution according to claim 19, wherein said
2 antibiotic metal ion is selected from the group consisting of silver, copper, zinc, mercury, tin,
3 lead, bismutin, cadmium, chromium and thallium.

1 21. An antibiotic coating solution according to claim 16, wherein said
2 antibiotic metal ion is selected from the group consisting of silver, copper, zinc, mercury, tin,
3 lead, bismutin, cadmium, chromium and thallium.

1 22. An antibiotic coating solution according to claim 16, wherein said
2 polymer further comprises an inorganic discoloration agent.

1 23. An antibiotic coating solution according to claim 22, wherein said
2 inorganic discoloration agent is ammonium.

1 24. An antibiotic coating solution according to claim 16, wherein said
2 antibiotic zeolite further comprises ion-exchanged ammonium ions.

1 25. An antibiotic coating solution according to claim 16, wherein said
2 organic solvent is selected from a group consisting of tetrahydrofuran, dimethylacetamide,
3 methylethylketone, and mixtures thereof.

1 26. An antibiotic coating solution according to claim 16, wherein said
2 coating solution comprises from about 0.01 to about 50% by weight solids.

1 27. An antibiotic coating solution according to claim 26, wherein said
2 coating solution comprises from about 0.1 to about 30% by weight solids.

1 28. An antibiotic coating solution according to claim 27, wherein said
2 coating solution comprises from about 1 to about 20% by weight solids.

1 29. An antibiotic coating solution according to claim 16, wherein the solids
2 of said coating solution comprise from about 0.01 to about 90% by weight of antibiotic zeolite.

1 30. An antibiotic coating solution according to claim 29, wherein the solids
2 of said coating solution comprise from about 0.05 to about 80% by weight of antibiotic zeolite.

1 31. An antibiotic coating solution according to claim 30, wherein the solids
2 of said coating solution comprise from about 0.1 to about 70% by weight of antibiotic zeolite.

1 32. An antibiotic coating solution according to claim 16, wherein the solids
2 of said coating solution comprise from about 10 to about 99.99% by weight of hydrophilic
3 polymer.

1 33. An antibiotic coating solution according to claim 32, wherein the solids
2 of said coating solution comprise from about 20 to about 99.95% by weight of hydrophilic
3 polymer.

1 34. An antibiotic coating solution according to claim 33, wherein the solids
2 of said coating solution comprise from about 30 to about 99.9% by weight of hydrophilic
3 polymer.

1 35. A method for coating an antibiotic hydrophilic coating on a substrate
2 comprising:

- 3 (a) providing an antibiotic hydrophilic coating solution comprising a
4 hydrophilic polymer, antibiotic zeolite dispersed therein, and an organic solvent; and
5 (b) applying said coating solution to said substrate.

1 36. A method for preparing an antibiotic hydrophilic coating on a substrate
2 according to claim 35, wherein during said applying step, said antibiotic zeolite is maintained
3 in suspension in said coating solution.

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 99/27273

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61L29/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | EP 0 781 566 A (TOYO BOSEKI) 2 July 1997 (1997-07-02) claims 1,4-10,22 page 6, line 38-47 | 1-12, 16-36 |
| X | US 5 698 229 A (OHSUMI SHUICHI ET AL) 16 December 1997 (1997-12-16) column 2, line 16 -column 4, line 7 column 7, line 8-32 | 1-11, 13-36 |
| X | US 4 938 958 A (NIIRA DECEASED REIJI ET AL) 3 July 1990 (1990-07-03) column 4, line 34 -column 5, line 3 claims | 1-10,14, 16-36 |
| | -/- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

10 April 2000

Date of mailing of the international search report

20/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Muñoz, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/27273

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|---|
| X | <p> DATABASE WPI Section Ch, Week 199725 Derwent Publications Ltd., London, GB; Class A82, AN 1997-276665 XP002135243 & JP 09 100205 A (NAKAMURA K), 15 April 1997 (1997-04-15) abstract </p> | <p> 1-11, 16-36 </p> |